8-KItem 2.02 · Results of OperationsItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
WEST PHARMACEUTICAL SERVICES INC (WST)

West Pharmaceutical Services files Form 8‑K (Feb 12, 2026) adding a Press Release (Ex.99.1) and Investor…

Filed with the SEC on · Summarized by InvestorsBot

West Pharmaceutical Services files Form 8‑K (Feb 12, 2026) adding a Press Release (Ex.99.1) and Investor Presentation (Ex.99.2). 📄 $WST #8K #Pharma

Item 9.01 exhibits: 99.1 Press Release (2/12/2026), 99.2 Presentation (2/12/2026) and cover page in Inline XBRL (Ex.104). Signed by CFO Robert W. McMahon on Feb 12, 2026. ✍️ $WST #SEC #Investing

This 8‑K under Item 9.01 contains only the listed exhibits (99.1, 99.2, 104); investors should review those documents for any material updates. 🔎 $WST #SEC #8K

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from WEST PHARMACEUTICAL SERVICES INC

West Pharmaceutical raises 2026 guidance after strong second-quarter results

8-K · July 23, 2026

West Pharmaceutical raises 2026 sales and adjusted EPS guidance after strong Q2

8-K · July 23, 2026

West Pharmaceutical ($WST) filed Form 8‑K (Item 9.01) to furnish a press release dated Mar 9, 2026…

8-K · March 9, 2026

West Pharmaceutical says Mr.

8-K · March 9, 2026

West Pharmaceutical Services ($WST) CEO/President/Chair Eric M.

8-K · March 9, 2026

WEST Pharmaceutical ($WST) filed a Regulation FD disclosure (Item 7.01) on 2026-02-12, incorporating Item…

8-K · February 12, 2026